Can you advertise medicinal cannabis in Australia?

Medicinal cannabis advertising in Australia is heavily restricted under the TGA framework and AHPRA National Law. Schedule 8 products cannot be promoted directly to consumers. Marketing must use unbranded strategies, educational content, and B2B prescriber outreach that comply with TGO 93 and AHPRA advertising guidelines to avoid significant financial penalties.

What is TGO 93 and how does it affect medicinal cannabis marketing?

TGO 93 (Therapeutic Goods Order No. 93) is the TGA's standard governing prescription medicine information. It restricts how Schedule 8 medicines, including medicinal cannabis, can be promoted. Direct-to-consumer advertising of prescription medications is prohibited. Compliant marketing must avoid efficacy or benefit claims entirely and focus on unbranded patient education or approved B2B prescriber communication.

What is a medicinal cannabis marketing agency?

A medicinal cannabis marketing agency is a specialist firm that develops marketing strategies for cannabis clinics, cultivators, and brands within Australia's regulated framework. Unlike general agencies, a specialist firm understands TGA compliance, AHPRA advertising rules, Schedule 8 promotion restrictions, and how to build patient acquisition and prescriber outreach systems that scale without regulatory risk.

How can medicinal cannabis clinics acquire patients legally in Australia?

Medicinal cannabis clinics in Australia can legally acquire patients through unbranded, condition-focused content marketing that educates patients on treatment options without directly promoting specific products. High-intent SEO targeting condition-based search terms, compliant landing pages, and referral-based funnels are the primary legal channels. All patient-facing content must avoid claims that breach AHPRA or TGA guidelines.

What are AHPRA's advertising rules for healthcare?

AHPRA prohibits testimonials that create unreasonable expectations, claims of guaranteed outcomes, misleading comparisons, and use of specialist titles without appropriate registration. For medicinal cannabis marketing, AHPRA compliance is critical — breaches can result in significant fines, registration conditions, or public regulatory findings against the practitioner or business.

Does SEKHN work with international brands entering the Australian cannabis market?

Yes. SEKHN provides Australian market entry strategy for international medicinal cannabis and healthcare brands, covering regulatory navigation, brand restructuring for the Australian context, and compliant growth architecture. Australia's medicinal cannabis market requires specific compliance knowledge that most international agencies do not possess.

What is a healthcare marketing agency and what does SEKHN do differently?

A healthcare marketing agency develops and executes marketing strategies for businesses operating in the health sector — including clinics, telehealth providers, allied health practices, pharmaceutical brands, and medicinal cannabis businesses. SEKHN differs by engineering every strategy, campaign, and content asset from the ground up around the regulatory realities of the Australian market, including AHPRA advertising guidelines, TGA regulations, and Schedule 8 product promotion restrictions.

Do I need a healthcare marketing agency or can a general digital agency handle my needs?

If your business operates under AHPRA or TGA jurisdiction, a general digital agency carries meaningful risk. A single non-compliant ad, a reshared testimonial that breaches guidelines, or a landing page with promotional language about a Schedule 8 product can constitute a regulatory breach with serious consequences. A specialist healthcare marketing agency with genuine compliance expertise removes that risk while still delivering the performance outcomes your business needs.

What types of healthcare businesses does SEKHN work with?

SEKHN works with medicinal cannabis businesses including licensed cultivators, clinics, and dispensaries; allied health practices across physiotherapy, psychology, occupational therapy, and related disciplines; cosmetic and dermatology clinics; dental practices; telehealth providers; pharmacies; and international healthcare brands entering the Australian market.

What does a healthcare marketing agency in Australia cost?

Pricing for a specialist healthcare marketing agency varies based on scope, channel mix, and the complexity of your regulatory environment. SEKHN works on a strategic retainer model tailored to each client's growth stage and objectives, beginning with a complimentary 30-minute strategy briefing.

How does SEKHN ensure marketing compliance with TGA and AHPRA regulations?

Compliance is the starting point of everything SEKHN builds, not a final check. Every campaign, landing page, content asset, and ad creative is assessed against TGA and AHPRA regulatory standards before going live. For medicinal cannabis clients, this includes specific attention to TGO 93, unbranded content requirements, and Schedule 8 product promotion restrictions.

Where is SEKHN based and do you work with clients outside Sydney?

SEKHN is headquartered in Sydney, NSW, and works with healthcare businesses across Australia including Melbourne, Brisbane, and Perth, as well as international brands entering the Australian healthcare market.

How quickly can a healthcare marketing agency deliver results?

Paid media and funnel optimisation typically produce measurable improvement within 30 to 90 days — most clients see a 30 to 60 percent improvement in booking conversion within that window. SEO and content-led strategies build over three to six months and produce compounding returns over time.

What the Next Round of TGA Reforms Mean from a Medicinal Cannabis Marketing Agency's Perspective.

rytashasekhon
Apr 30
5 min read

And your ad strategy could be in the crosshairs

Regulatory reform in Australian healthcare arrives with a paper trail, and right now, that trail is getting a lot more interesting for anyone running, advising, or marketing a medicinal cannabis business. A couple of weeks ago, a Cannabiz article mentioned that the TGA is finalising a safety assessment report on medicinal cannabis and psychosis. Regulatory reform in Australian healthcare doesn't arrive with a press conference. It arrives with a paper trail. And right now, that trail is getting a lot more interesting for anyone running, advising, or marketing a medicinal cannabis business. It was flagged inside a discussion paper at last month's Advisory Committee on Medicines Scheduling (ACMS) meeting – if you've been in the industry long enough, you know what that means. For everyone else, here's the translation.

What's actually happening in plain English.

The ACMS is the body that recommends scheduling changes to the Poisons Standard. When the TGA commissions a safety assessment and walks it into an ACMS meeting via a discussion paper, that's the formal pathway by which regulatory reforms get proposed.

Think of it as the moment the regulator stops asking questions in the hallway and starts setting an agenda.

The framing matters too. Why psychosis? Because it's a clinically and politically charged stick and one regulators can use to justify a much broader sweep. It ties neatly into concerns the TGA has been quietly cataloguing for years: vertical-clinic models, ballooning prescribing volumes, the well-documented overpopulation of telehealth businesses, and – most relevantly for this conversation – an endless list of advertising breaches.

For context: in the last two years alone, the TGA has issued more than 165 infringement notices and commenced multiple civil penalty proceedings, totalling over $2.3 million in penalties for unlawful medicinal cannabis advertising.

What likely comes next, on a spectrum

We won't know the full picture until the safety report is published and the ACMS outcomes follow. But the shape of the reform is reasonably predictable. Here's the spectrum we'd be planning around:

Light end: Tighter prescribing criteria. Tougher mental health screening before initiation. A noticeable tightening of advertising rules and we'd take a confident bet that "natural medicine," "plant medicine," and similar soft-language workarounds are first on the chopping block. The TGA has already updated its advertising guidance to capture synonymous terminology, and a fresh report is exactly the cover the regulator needs to harden that line.

Heavier end: Dose caps. Age restrictions (young adults are the obvious target, given the psychosis framing). Partial rescheduling of specific product classes. Restrictions on who can prescribe, and under what model.

The spectrum matters because your response shouldn't be the same at both ends. Light-end reform is a content and creative problem. Heavier-end reform is a whole business model problem.

Why this is really an advertising story

Here's the part most business owners in this space are missing.

When regulators want to change behaviour in a prescription-only category, advertising is almost always the first lever they pull. Why? because it's visible, it's measurable, and it's the area where breaches are easiest to prove.

The TGA has been telegraphing this for two years through escalating fines, court proceedings against clinics and the lifestyle media outlets that ran their advertorials, and increasingly granular guidance about what constitutes an "advertisement."

The current rules already prohibit:

Advertising prescription-only medicines (which includes medicinal cannabis) directly to consumers
Use of synonymous terms like "plant medicine" or "plant-based medicine"
Implied claims about treating anxiety, depression, PTSD, chronic pain, or other restricted representations
Using imagery, business names, or logos that promote supply or use

Once you read the safety report through that lens, the next round of reform writes itself. Tighter language rules. More aggressive interpretation of what counts as "indirect" advertising. Possibly a clamp on patient testimonials about services, founder stories that double as product positioning, and the ever-popular "education hub" that's really a funnel.

Most clinics have built their patient acquisition machine inside this grey zone but it's about to rapidly turn black and white. The truth is, if a clinic's strategy depended on purely language gymnastics, they're going to start finding it a lot harder to stay afloat.

The moat hiding inside the reform

Here's the contrarian read, and the one we, as a marketing agency, would give our clients:

This is your moat.

Right now, the medicinal cannabis space looks pretty much like a copy-paste exercise. Everyone has the same earthy pallet, the same sans-serif font, the same three lifestyle photographt cues, and the same "natural medicine" framing pushed out. Clinics and brands aren't competing on brand identity (because there really is none), they're competing purely on advertising spend, service pricing, and word-of-mouth. If your mate goes to Astrid Clinic and rates it, then wouldn't that automatically bump it up on your list?

But guess what? The tighter rules are going to wipe out the bottom half of that field. The operators whose entire business model is built on borderline language and lifestyle imagery will likely spend the next 18 months in cleanup mode. Some won't survive it. The ones who do will look exactly like everyone else who survived because they all rebuilt around the same compliance template.

And that's the gap.

If you're serious about growing your business, then you need a medicinal cannabis marketing agency that isn't just writing copy but one that is building a brand architecture that can survive any reasonable interpretation of the next reform. That means proper brand positioning instead of ingredient theatre. It means trust signals that are actually about clinical credibility, not borrowed wellness aesthetics. It means content that educates without selling, and visual systems that don't lean on the plant for personality because the plant is exactly what you're not allowed to lean on.

You can't win a regulated category with the same playbook everyone else is running. You win by treating compliance as a creative constraint, not a creative ceiling.

Advice from a medicinal cannabis marketing agency

Three moves, in order of urgency:

Audit your full surface area against the existing rules. Website, socials, landing pages, paid media, founder LinkedIn, patient case studies, any "education" content, third-party advertorials, podcast sponsorships, every form of indirect advertising the TGA has signalled it cares about. Audit the headlines AND the implications. A good litmus test is whether a consumer would interpret material as promoting supply or use, and if so, it needs to be axed.

Build the brand layer. Voice, positioning, design system, clinical narrative, founder story, organisational values – all the parts of a brand that don't depend on what you can or can't say about the product. This is the part that most owners skip because it takes really knowing the industry and what the heck to say. It's much easier to ride on the coattails of grey language as every other clinic.

Pre-empt the heavier-end scenarios. If dose caps or age restrictions land, what does your patient mix look like? What does your unit economics look like? Which acquisition channels go to zero, and which get more valuable?

To learn more about what a medicinal cannabis marketing agency does, check out another article here or alternatively, browse through our services.

SEKHN is a marketing and brand consultancy working at the edge of regulated industries in Australia. We help medicinal cannabis operators, telehealth businesses, and adjacent healthcare brands build positioning and patient acquistion architecture that survives regulation and stands out inside it.